Applied Regulatory Science Research to Evaluate Cardiotoxicity of Oncology Therapeutics (U01) Clinical Trial Optional
This grant opportunity is designed to fund research that improves the detection and monitoring of heart-related side effects caused by cancer treatments.
Source
Award
Dates
Eligibility
Keywords
Supporting Links
Documents
Similar Opportunities
-
Applied regulatory science research to evaluate and treat cardiotoxicity of oncology therapeutics
Food and Drug Administration
-
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
National Institutes of Health ▸ National Cancer Institute
-
NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
National Institutes of Health ▸ National Center for Complementary and Integrative Health
-
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health ▸ National Cancer Institute
-
High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
National Institutes of Health ▸ National Institute on Drug Abuse
Find tens of thousands more opportunities — free
Scout accounts are free. Sign up to browse the full funding database, unlock the solicitation links and documents for this opportunity, and see how well each one fits your organization.
-
Tens of thousands of funding opportunities
Search and filter every grant and solicitation in Scout — all free, no credit card required.
-
Instant Fit Analysis
Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
-
Source links & full documents
Jump straight to the solicitation and download every attachment.
-
Save opportunities & track deadlines
Keep the opportunities that fit in one place and stay ahead of every due date.
Already have an account? Sign In
Trusted by 500+ Happy Customers